PTGS2 and metabolic dysfunction-associated steatotic liver disease: Consistent with a pro‐inflammatory role in chronic liver diseases,8 the temporal profile of enhanced cyclooxygenase 2 (COX‐2) expression paralleled the progression of NAFLD in rodent models,9 implying that COX‐2 and other pro‐inflammatory factors involved could be therapeutic targets for single agents or combination regimens intended to achieve disease remission and reversal.